Cardiol Therapeutics Inc. (CRDL) vs Nyxoah S.A. (NYXH)

A side-by-side comparison of Cardiol Therapeutics Inc. and Nyxoah S.A. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CRDL vs NYXH

growth of $100 · dividends reinvested · last 5y
CRDL -56.1% (-15.2%/yr)NYXH -94.1% (-43.3%/yr)CRDL compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020222023202420252026$44$6
CRDL NYXH

CRDL vs NYXH: by the numbers

  • •CRDL is the larger company ($151M vs $143M market cap).
  • •Both run net losses; CRDL's is the smaller (0.00% vs -435.70% net margin).

Metrics side by side

Valuation

MetricCRDLNYXH
P/S ratioN/A5.46
P/B ratio8.921.51

Profitability

MetricCRDLNYXH
Gross margin0.00%63.13%
Operating margin0.00%-827.76%
Net margin0.00%-435.70%
ROE-155.34%-120.33%
ROIC-165.56%-61.13%

Growth (annualized)

MetricCRDLNYXH
Revenue CAGR (5Y)N/A120.68%
Total return CAGR (5Y)-18.36%-45.84%

Frequently asked

How have CRDL and NYXH total returns compared?
Over the past 5 years, CRDL delivered -18.36% and NYXH delivered -45.84% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.